FDA Classified Thyroid Tablet Recall As Class I

The FDA elevated the recall for Vitruvias Therapeutics thyroid tablets due to potential superpotency risks.

Updated on Sept. 24, 2026 in Healthcare

Isometric editorial illustration of a glass beaker holding small white discs on a white surface, representing pharmaceutical oversight. — The FDA has classified a recall of thyroid tablets from Vitruvias Therapeutics as Class I, warning of severe risks due to potential superpotency. AI Illustration. Upload story photo >

Live Poll

Do you trust pharmaceutical companies to ensure drug safety even after they cease operations?

The FDA reclassified a recall of thyroid tablets from Vitruvias Therapeutics to Class I after the company ceased operations. The affected medication poses significant health risks due to potential superpotency, particularly for elderly patients and pregnant women.

Why it matters

A Class I designation represents the most serious recall level, indicating a reasonable probability that the use of these products will cause serious adverse health consequences or death. This action addresses safety concerns arising from the manufacturer's closure and the subsequent need for secure product disposal.

The recall involves lot number 504950, consisting of approximately 2,000 distributed bottles. These tablets, which carry an expiration date of Sept. 30, 2026, were distributed across the United States.

The players

FDA

The Food and Drug Administration is a federal agency responsible for protecting public health by ensuring the safety and efficacy of human drugs and biological products.

Vitruvias Therapeutics

This pharmaceutical company focused on developing and marketing generic medications before ceasing all business operations.

H2-Pharma LLC

This company is responsible for the ongoing ownership and distribution of product lines formerly managed by Vitruvias Therapeutics.

The details

Vitruvias Therapeutics has notified wholesalers to cease all distribution of the affected thyroid tablets and destroy remaining inventory. Because the company has stopped all business operations, H2-Pharma LLC now manages the distribution and oversight of its former product lines.

Jan. 31, 2025: Distribution of the affected lot began.
Sept. 30, 2025: Distribution of the medication concluded.
Summer 2026: The initial voluntary recall was announced.
Sept. 23, 2026: The FDA officially reclassified the recall to Class I.
Sept. 30, 2026: The affected medication reaches its labeled expiration date.

Market Landscape

This recall highlights the operational vulnerabilities in the generic drug supply chain when manufacturers exit the market. It follows established protocols for maintaining patient safety during corporate dissolutions.

Consumers should check their medication bottles for lot number 504950 and stop using them immediately if they match. Patients are encouraged to contact their healthcare provider to discuss safe alternatives and ensure their continued treatment stability.

The takeaway

Patients currently taking thyroid medication should verify their product details with their pharmacist to ensure they are not using affected lot numbers. When a manufacturer ceases operations, the FDA takes an active role in overseeing the removal of potentially unsafe inventory from the market.